These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2563302)

  • 1. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
    Ford JM; Prozialeck WC; Hait WN
    Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
    Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
    Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C.
    Aftab DT; Ballas LM; Loomis CR; Hait WN
    Mol Pharmacol; 1991 Nov; 40(5):798-805. PubMed ID: 1944244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
    Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
    Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
    Molnár J; Hevér A; Fakla I; Fischer J; Ocsovski I; Aszalós A
    Anticancer Res; 1997; 17(1A):481-6. PubMed ID: 9066699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
    Thimmaiah KN; Jayashree BS; Germain GS; Houghton PJ; Horton JK
    Oncol Res; 1998; 10(1):29-41. PubMed ID: 9613455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
    Lee Y; Yeo H; Liu SH; Jiang Z; Savizky RM; Austin DJ; Cheng YC
    J Med Chem; 2004 Oct; 47(22):5555-66. PubMed ID: 15481991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The primary in vitro antitumor screening of "half-mustard type" phenothiazines.
    Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Nacsa J; Molnár J
    Anticancer Res; 1997; 17(5A):3409-23. PubMed ID: 9413180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity.
    Hendrich AB; Wesołowska O; Poła A; Motohashi N; Molnár J; Michalak K
    Mol Membr Biol; 2003; 20(1):53-60. PubMed ID: 12745926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
    Hait WN; Pierson NR
    Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensely potent doxorubicin analogues: structure-activity relationship.
    Farquhar D; Cherif A; Bakina E; Nelson JA
    J Med Chem; 1998 Mar; 41(6):965-72. PubMed ID: 9526570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
    Coley HM; Twentyman PR; Workman P
    Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of P-glycoprotein transport function by N-acylphenothiazines.
    Wesolowska O; Molnár J; Motohashi N; Michalak K
    Anticancer Res; 2002; 22(5):2863-7. PubMed ID: 12530010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J; Wang FP; Wei H; Liu G
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G; Waxman DJ
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.
    Hait WN; Aftab DT
    Biochem Pharmacol; 1992 Jan; 43(1):103-7. PubMed ID: 1346493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.